title: Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
authors.affiliation: Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Miami, Florida 33101-5809, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Pinna
authors.forename: D
authors.initials: D
authors.lastname: Weppler
authors.forename: J R
authors.initials: JR
authors.lastname: Nery
authors.forename: F
authors.initials: F
authors.lastname: Khan
authors.forename: P
authors.initials: P
authors.lastname: Ruiz
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: W
authors.initials: W
authors.lastname: De Faria
authors.forename: M
authors.initials: M
authors.lastname: Berho
authors.forename: A G
authors.initials: AG
authors.lastname: Tzakis
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003520:Cyclophosphamide / Q000627:therapeutic use; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007422:Intestines / Q000637:transplantation*; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000276:immunology / Q000401:mortality / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003520:Cyclophosphamide; D000077561:Daclizumab; D009173:Mycophenolic Acid